mechanism of action of glp-1 receptor agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Mechanisms of Action and Therapeutic
Description
doi: 10.2337/dc17-1956 16 BrownEHeerspinkHJLCuthbertsonDJWildingJPH
GLP-1 treatment was not statistically significantly different compared to control at reducing the risk of developing dry AMD at one and three years after treatment, but GLP-1 receptor agonists did lower dry AMD risk at five and 10 years after treatment by 9.2% and 14.9%, respectively
P., Heller R
[DOI] [PubMed] [Google Scholar] 459.Hothersall J.D., Brown A.J., Dale I., Rawlins P
